Newly Developed Mobile Phone Device Reads ELISA Plates
By LabMedica International staff writers Posted on 17 Aug 2015 |
Image: The new miniature ELISA microplate reader device is created with a 3-D printer and attaches to a smartphone, enabling clinicians to perform lower-cost rapid diagnostic ELISA tests at point-of-care, including in many resource-poor or field settings (Photo courtesy of UCLA).
A multidisciplinary team of scientists and clinicians have developed a handheld smartphone-based device that can quickly read standard 96-well microplates with the same level of accuracy as the platforms commonly used in central clinical laboratories. The device, made by 3-D printing, attaches to the smartphone.
The research team from the University of California Los Angeles (UCLA; Los Angeles, CA, USA), led by Prof. Aydogan Ozcan along with Prof. Dino Di Carlo and Prof. Omai Garner, developed the ELISA reader to enable clinicians to perform these tests at lower cost and with greater flexibility for testing at point-of-care (POC), including in many resource-poor or field settings. “It is quite important to have these kinds of mobile devices, especially for administering medical tests that are usually done in a hospital or clinical laboratory,” said Prof. Ozcan, “This mobile platform can be used for point-of-care testing, screening populations for particular diseases, or tracking vaccination campaigns in most resource-poor settings.”
ELISA testing is most commonly performed with the standard 96-well transparent plastic plates that resemble honeycombs. The new device illuminates the plate with an array of light-emitting diodes (LEDs). The light projected through each well is collected by 96 individual plastic optical fibers. The smartphone transmits the resulting images to UCLA servers through a custom-designed app. The images are then analyzed by a machine-learning algorithm and the results are sent back to the phone for viewing within about 1 minute for the entire 96-well plate.
This mobile platform was compared with the standard FDA-approved well-plate readers at a UCLA clinical microbiology laboratory. The comparison included ELISA tests for mumps, measles, and herpes simplex viruses 1 and 2. Of a total of 571 patient samples, the mobile platform achieved 99.6% accuracy in diagnosing mumps, 98.6% for measles, and 99.4% each for herpes simplex 1 and 2.
“Our team is focused on developing biomedical technologies that work with mobile platforms to assist with on-site testing and health-care in disadvantaged or rural areas,” said Mr. Berg. Prof. Di Carlo added, “We are always looking toward the next innovation, and are looking to adapt the basic design of this ELISA cellphone reader to create smartphone-based quantified readers for other important medical tests.”
The work, by Berg B, et al, was reported online July 9, 2015, in the American Chemical Society journal ACS Nano.
Related Links:
UCLA
California NanoSystems Institute (at UCLA and UCSB)
The research team from the University of California Los Angeles (UCLA; Los Angeles, CA, USA), led by Prof. Aydogan Ozcan along with Prof. Dino Di Carlo and Prof. Omai Garner, developed the ELISA reader to enable clinicians to perform these tests at lower cost and with greater flexibility for testing at point-of-care (POC), including in many resource-poor or field settings. “It is quite important to have these kinds of mobile devices, especially for administering medical tests that are usually done in a hospital or clinical laboratory,” said Prof. Ozcan, “This mobile platform can be used for point-of-care testing, screening populations for particular diseases, or tracking vaccination campaigns in most resource-poor settings.”
ELISA testing is most commonly performed with the standard 96-well transparent plastic plates that resemble honeycombs. The new device illuminates the plate with an array of light-emitting diodes (LEDs). The light projected through each well is collected by 96 individual plastic optical fibers. The smartphone transmits the resulting images to UCLA servers through a custom-designed app. The images are then analyzed by a machine-learning algorithm and the results are sent back to the phone for viewing within about 1 minute for the entire 96-well plate.
This mobile platform was compared with the standard FDA-approved well-plate readers at a UCLA clinical microbiology laboratory. The comparison included ELISA tests for mumps, measles, and herpes simplex viruses 1 and 2. Of a total of 571 patient samples, the mobile platform achieved 99.6% accuracy in diagnosing mumps, 98.6% for measles, and 99.4% each for herpes simplex 1 and 2.
“Our team is focused on developing biomedical technologies that work with mobile platforms to assist with on-site testing and health-care in disadvantaged or rural areas,” said Mr. Berg. Prof. Di Carlo added, “We are always looking toward the next innovation, and are looking to adapt the basic design of this ELISA cellphone reader to create smartphone-based quantified readers for other important medical tests.”
The work, by Berg B, et al, was reported online July 9, 2015, in the American Chemical Society journal ACS Nano.
Related Links:
UCLA
California NanoSystems Institute (at UCLA and UCSB)
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms